


QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09777526</u>	Prepared by <u>owc</u>	Tracking Number <u>05993405</u>	
Examiner-GAU <u>Le Guyader</u>	Date <u>8/20/04</u>	Week Date <u>8-09-04</u>	
<u>1635</u>	No. of queries <u>-1-</u>	<u>IFW</u>	

JACKET			
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION	
a. Page Missing	MESSAGE <u>PTO-1449</u>
b. Text Continuity	<u>Please either initial or line</u>
c. Holes through Data	<u>through citations - See attached copies</u>
d. Other Missing Text	<u>Thank you</u>
e. Illegible Text	<u>owc</u>
f. Duplicate Text	
g. Brief Description	
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	
d. Incorrect Numbering	
e. Index Disagrees	initials
f. Punctuation	RESPONSE
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

1

OF

4

Docket Number
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal et al.Filing Date
February 6, 2001Group Art Unit
1635

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,309,404	1/5/1982	DeNeale et al.	424	21	
	4,309,406	1/5/1982	Guley et al.	424	21	
	4,556,552	12/3/1985	Porter et al.	424	32	
	4,704,295	11/3/1987	Porter et al.	427	3	
	5,220,007	6/15/1993	Pederson et al.	536	23.1	
	5,149,797	9/22/1992	Pederson et al.	536	23.1	
	5,220,007	12/21/1993	Cho-Chung	424	450	
	5,248,670	9/28/1993	Draper et al.	514	44	
	5,271,941	12/21/1993	Cho-Chung	424	450	
	5,403,709	10/6/1992	Agrawal et al.	435	6	
	5,442,049	8/15/1995	Anderson et al.	536	24.5	
	5,470,967	11/28/1995	Huie et al.	536	24.3	
	5,514,577	5/7/1996	Draper et al.	435	238	
	5,578,716	12/1/1993	Szyf et al.	536	24.5	
	5,612,212	11/12/1993	Gewirtz	435	456	
	6,143,881	11/7/2000	Metelev et al.	536	24.5	
	5,652,355	7/29/1997	Metelev et al.	536	24.5	
	5,969,117	10/19/1999	Agrawal	536	22.1	

RECEIVED

MAY 28 2001

TECH CENTER 1600/2900

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	94/02498	2/3/1994	WO	C07H 21	00		X
	94/15619	7/21/1994	WO	A61K 31	70		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Agrawal, Sudhir, "Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups." <i>Methods Mol Biol.</i> , Vol. 26, pp. 93-120 (1994)
A2	Agrawal et al., "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues." <i>Proc Natl Acad Sci U S A.</i> , Vol. 86, No. 20, pp. 7790-4 (1989)
A3	Agrawal, <u>Antisense Therapeutics</u> , (Sudhir Agrawal, ed.), Page V (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subl. For, PTO-1449		Docket Number HYZ-030CPCN3	Application Number 09/777,526
INFORMATION DISCLOSURE IN AN APPLICATION MAY 21 2001 (Use several sheets if necessary)		Applicant Agrawal et al.	
		Filing Date February 6, 2001	Group 1635
3	OF	4	

RECEIVED

MAY 23 2001

TECH CENTER 1600/2000

B17	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H." <i>FEBS Lett.</i> , Vol. 215, No. 2, pp. 327-30 (1987)
B18	Inoue et al., <i>FEBS Lett.</i> , Vol. 215, pp. 237-250 (1987)
B19	Iversen, "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue." <i>Anticancer Drug Des.</i> , Vol. 6, No. 6, pp. 531-8 (1991)
C1	Iversen, "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion." <i>Antisense Res Dev.</i> , Vol. 4, No. 1, pp. 43-52 (1994)
C2	Kawasaki et al., "Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets." <i>J Med Chem.</i> , Vol. 36, No.7, pp. 831-41 (1993)
C3	Levin (10/8-9/98) Antisense 98, Targeting the Molecular Basis of Disease, pp. 25
C4	Martin, P. <i>Helvetica Chimica Acta</i> , 78: 486-504 (1995)
C5	Meteliev et al, <i>Bioorganic & Medicinal Chemistry Letters</i> , 4: 2929-2934 (1994)
C6	Milligan et al., "Current concepts in antisense drug design." <i>J Med Chem.</i> , Vol. 36, No. 14, pp. 1923-37 (1993)
C7	Orr, (Reported By) Antisense 98: "Targeting the Molecular Basis of Disease (Part III)" Organized by Nature Biology, London, UK (1988)
C8	Quartin et al., "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates." <i>Nucleic Acids Res.</i> , Vol. 17, No. 18, pp. 7253-62 (1989)
C9	Rapaport et al., "Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant <i>Plasmodium falciparum</i> ." <i>Proc Natl Acad Sci U S A.</i> , Vol. 89, No. 18, pp. 8577-80 (1992)
C10	Sands, "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate." <i>Mol Pharmacol.</i> , Vol. 45, No. 5, pp. 932-43 (1994)
C11	Shibahara et al., "Site-directed cleavage of RNA." <i>Nucleic Acids Res.</i> , Vol. 15, No. 11, pp. 4403-15 (1987)
C12	Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives." <i>Nucleic Acids Res.</i> , Vol. 17, No. 1, pp. 239-52 (1989)
C13	Shibahara et al., <i>Nucleic Acids Res.</i> , Vol. 15, pp. 4403-4415 (1987)
C14	Sonveaux, "Protecting Groups in Oligonucleotide Synthesis", in <i>Methods in Molecular Biology</i> (Agrawal ed.) 26:1-71 (1994)
C15	Stein et al., "Antisense oligonucleotides as therapeutic agents--is the bullet really magical?" <i>Science</i> , Vol. 261, No. 5124, pp. 1004-12 (1993)
C16	Takashima et al., "Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity." <i>Proc Natl Acad Sci U S A.</i> , Vol. 90, No. 16, pp. 7789-93 (1993)
C17	Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups." <i>Br J Cancer.</i> , Vol. 60, No. 3, pp. 343-50 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

 Docket Number
 HYZ-030CPCN3

 Application Number
 09/777,526

 Applicant
 Agrawal et al.

 Filing Date
 February 6, 2001

 Group Art Unit
 1635

	C18	Tortora et al., "Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production." <i>Clin Cancer Res.</i> Vol. 6, No. 6, pp. 2506-12 (2000)
	C19	Tseng et al., "Antisense oligonucleotide technology in the development of cancer therapeutics." <i>Cancer Gene Ther.</i> ; Vol. 1, pp. 65-71 (1994)
	C20	Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle" <i>Chem. Rev.</i> Vol. 90, pp. 543-584 (1990)
	D1	Wang et al., "Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the R1alpha subunit of protein kinase A after oral administration." <i>Proc Natl Acad Sci U S A.</i> , Vol. 96, No. 24, pp. 13989-94 (1999)
	D2	Wickstrom, E., "Oligodeoxynucleotide stability in subcellular extracts and culture media." <i>J Biochem Biophys Methods.</i> , Vol. 13, No. 2, pp. 97-102. (1986)
	D3	Wickstrom, E., "Strategies for administering targeted therapeutic oligodeoxynucleotides." <i>Trends Biotechnol.</i> , Vol. 10, No. 8, pp. 281-7(1992)
	D4	Zamecnic, P., "History of Antisense Oligonucleotides" in <i>Antisense Therapeutics</i> (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996) pp. 1-11.
	D5	Zhao et al., <i>Antisense Res. and Dev.</i> 3: 53-66 (1993)
	D6	Zon, <i>Pharm.Res</i> 5(9): 539-49 (1988)
	D7	Zendegui et al., "In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides." <i>Nucleic Acids Res.</i> , Vol. 20, No. 2, pp. 307-14 (1992)

RECEIVED
 MAY 23 2001
 TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	